Alpha Registry
Claim a profile

Executive profile

Public information reviewed

Ronald E. Osman

Director at Inhibitor Therapeutics, Inc. (OTC: INTI)

Inhibitor Therapeutics, Inc. (OTC: INTI)

Director · Current mandate

Executive
FollowSave PDF
More
Reports & analysisAlpha EvalAsk Alpha

Profile information

Public identity reviewed. Profile ownership pending.

Verification
Source reported
Published claims
7
Public source records
2
Evidence links
7
Last reviewed
May 16, 2026
Public sources
2 reviewed
Profile ownership
Not yet claimed
Last reviewed
May 16, 2026
View sources

Governance brief

Alpha Profile

Canonical ID
alpha:person:ronald-e-osman
Published claims
7
Mandate and committee claims
4
Evidence sources
2
Last reviewed
May 16, 2026
Verification
Source reported

Counts describe published records, not completeness. Missing fields remain unknown, not zero.

Record coverage summary

  • identityPublished
  • businessNot applicable
  • leadershipPublished
  • board and committeesPublished
  • governancePublished
  • financialsNot applicable
  • workforceNot applicable
  • ownershipNot applicable
  • EvalsNot published
  • market and index contextNot applicable

Public retrieval: Allowed · Agent retrieval: Allowed · Redistribution: Not granted

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Alpha has not published a narrative summary because the current public source set is not sufficient.

Top skills · Alpha-derived

Derived from the published roles, board service, education, and cited sources in this profile. These descriptors are analytical signals, not endorsements or verified proficiency levels.

Assertion
Alpha inference
Publication
Published
Basis
Governed public record
  • Executive
  • Director

Current roles

Leadership now

Director

Inhibitor Therapeutics, Inc. (OTC: INTI)

Current

Confirmed by public sourceView source

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec Form OwnershipPublic profile sourceSupports Director at Inhibitor Therapeutics, Inc. (OTC: INTI).Open sourceSource 2 · Sec FilingINTI 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open source

Public professional graph

Network lens

Published affiliations, capability adjacency, and evidence-labelled relationship signals. Private familiarity or influence is not asserted.

Career architecture

Unavailable

No published career records are available for this profile.

unavailable · 0 evidence records

Governance portfolio

Not asserted

The governed public source set does not establish a board or advisory portfolio.

unavailable · 0 evidence records

Capability graph

Unavailable

No public capability taxonomy is attached to this profile.

unavailable · 0 evidence records

Public affiliation breadth

Unavailable

This is a count of published company affiliations, not a measure of influence or relationship strength.

unavailable · 0 evidence records

Temporal relationship trace

Published affiliations

Unavailable · no published affiliation series is attached to this record.

Capability adjacency

Published areas

    Unavailable · no public capability taxonomy is attached.

    Direct contact, private mutual connections, and relationship pathfinding are not exposed.

    Relationship map

    Connected through the public record

    Direct relationships from verified facts and published résumé records. Private connections are excluded.

    • Inhibitor Therapeutics, Inc.

      Director

      Verified public fact

    Direct public links only

    AGKG relationship pathfinding is not granted on this public profile. Deeper paths belong in a permissioned workspace.

    Sources

    Sources and published information

    Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

    AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
    Verification
    Source reported
    Confidence
    72%
    Last reviewed
    May 16, 2026
    • SEC EDGAR

      Sec Filing · Tier 3 · Reviewed May 16, 2026

    Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
    Verification
    Source reported
    Confidence
    72%
    Last reviewed
    May 16, 2026
    • SEC EDGAR

      Sec Filing · Tier 3 · Reviewed May 16, 2026

    Executive company · Source reportedExecutive at Inhibitor Therapeutics, Inc.1 source
    Verification
    Source reported
    Confidence
    94%
    Last reviewed
    May 16, 2026
    • SEC EDGAR

      Sec Filing · Tier 3 · Reviewed May 16, 2026

    Executive title · Source reportedExecutive title: Director1 source
    Verification
    Source reported
    Confidence
    94%
    Last reviewed
    May 16, 2026
    • SEC EDGAR

      Sec Filing · Tier 3 · Reviewed May 16, 2026

    Other Company Role · Source reportedRonald E. Osman is also linked to Cell Culture, Inc. (C3) as Chairman of the Board.1 source
    Verification
    Source reported
    Confidence
    70%
    Last reviewed
    May 16, 2026
    • SEC EDGAR

      Sec Filing · Tier 3 · Reviewed May 16, 2026

    Technology background · Source reportedTechnology background: not identified in the cited filing1 source
    Verification
    Source reported
    Confidence
    72%
    Last reviewed
    May 16, 2026
    • SEC EDGAR

      Sec Filing · Tier 3 · Reviewed May 16, 2026

    View all sources2 records
    1. https://www.sec.gov/Archives/edgar/data/1042418/000149315226035962/ownership.xml

      Sec Form Ownership · Tier not stated · Reviewed Aug 6, 2026

      Supports: Director at Inhibitor Therapeutics, Inc. (OTC: INTI)

    2. SEC EDGAR

      Sec Filing · Tier 3 · Reviewed May 16, 2026

      Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background